查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1301033

临床肿瘤学下一代测序市场规模、份额和趋势分析报告：按工作流程（NGS 预测序、NGS 数据分析）、按技术、按应用、按最终用途、按地区、细分市场趋势，2023-2030 年

Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-sequencing, NGS Data Analysis), By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

临床肿瘤学下一代测序市场增长和趋势

根据 Grand View Research, Inc. 的最新报告，预计到 2030 年，全球临床肿瘤学下一代测序市场将达到 11.6 亿美元。

从 2023 年到 2030 年，市场预计将以 15.7% 的复合年增长率扩张。 临床肿瘤学下一代测序（NGS）市场需求量很大。 由于有效的个性化医疗和癌症治疗方法的开发以及医疗保健支出的增加引发了 NGS 采用的增加，预计增长率在预测期内将会增加。

不断上涨的医疗保健成本和有效癌症治疗方法的出现预计将在预测期内推动市场增长。 JAMA Network 于 2023 年 2 月发表的一项研究估计，2020 年至 2030 年 30 年间，全球癌症治疗费用将高达 25 万亿美元。 研究发现，高收入国家治疗费用对癌症总经济支出的相对贡献高于低收入国家。 此外，正在开发各种治疗技术并将其用于癌症的诊断和治疗。 根据 Wiley 2023 年 1 月发表的一项研究，用于开发新诊断技术的技术进步包括图像重建软件、诊断成像设备、硬件、生物标誌物和人工智能算法，从而能够对肿瘤进行可靠的分析和诊断。

此外，在预测期内，NGS 相对于单基因检测的日益普及也推动了临床肿瘤学下一代测序市场的增长。 大量研究表明，NGS 比单基因检测更具成本效益和效率。 例如，JCO Precision Oncology 于 2023 年 3 月发表的一项研究发现，在西班牙参考中心采用 NGS 诊断 NSCLC 患者是比单基因检测更具成本效益的策略。我的结论是。 此外，国家医学图书馆于 2023 年 1 月进行的一项研究表明，当前 NGS 的年度成本略低于序贯单基因检测。 然而，采用 NSG 测试而不是 SSG 测试可以缩短平均交付时间，有利于日本小细胞肺癌患者快速识别基因组改变并儘早开始治疗。 预计这些因素将在预测期内推动市场。

临床肿瘤学下一代测序市场报告亮点

  • 在工作流程领域，由于技术进步和癌症测序项目的增加，NGS 测序将在 2022 年以 56.0% 的销售份额占据市场主导地位
  • 按技术划分，2022 年，靶向测序和重测序在临床肿瘤 NGS 市场中占据最大收入份额，达到 72.7%。 这是由于靶向组的临床实用性增加和癌症肿瘤检测的高效率。
  • 从应用来看，2022年筛查领域占比最高，达到80.1%。 该细分市场的主导地位是全球癌症患病率的又一次上升。
  • 按最终用途划分，到 2022 年，实验室领域将占据临床肿瘤 NGS 市场的最大份额，达到 64.1%。 这是由于研究和开发活动的增加。
  • 2022 年，北美市场份额最大，达到 48.68%。 该地区的主导地位部分归因于市场上知名国际参与者的存在，以及公共和私人机构对该地区生命科学研究和解决方案开发的投资不断增加。

内容

第1章调查方法及范围

  • 信息获取
  • 信息或数据分析
  • 市场范围和细分定义
  • 市场模式
    • 按公司市场份额进行市场调查
    • 区域分析

第 2 章执行摘要

  • 市场概况
  • 片段快照
  • 竞争格局快照

第3章市场变量、趋势和范围

  • 市场体系展望
    • 母公司市场前景
    • 相关/补充市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场製约因素分析
  • 行业分析工具
    • SWOT 分析：按因素（政治/法律、经济/技术）
    • 波特五力分析
    • 2022 年采用率和增长前景图
  • COVID-19 的影响分析

第 4 章临床肿瘤学下一代测序市场分类：技术评估和趋势分析

  • 临床肿瘤学NGS市场：技术波动分析
  • 按技术
  • 全基因组测序
    • 临床肿瘤学市场的全基因组测序，2018-2030 年（百万美元）
  • 全外显子组测序
    • 2018-2030 年临床肿瘤学市场的全外显子组测序（百万美元）
  • 靶向测序和重测序
    • 2018-2030 年临床肿瘤市场的靶向测序和重测序（百万美元）

第 5 章临床肿瘤学下一代测序市场分类：工作流程估计和趋势分析

  • 临床肿瘤学 NGS 市场：工作流程变化分析
  • 按工作流程
  • NGS 预测序
    • 2018-2030 年临床肿瘤学市场的 NGS 预测序（百万美元）
  • NGS 序列
    • 2018-2030 年临床肿瘤学市场的 NGS 测序（百万美元）
  • NGS数据分析
    • 2018-2030 年临床肿瘤市场 NGS 数据分析（百万美元）

第 6 章临床肿瘤学下一代测序市场分类：应用估算和趋势分析

  • 临床肿瘤学 NGS 市场：应用变化分析
  • 按最终用途
  • 筛选
    • 2018-2030 年临床肿瘤学 NGS 市场筛查（百万美元）
    • 散发性癌症
    • 遗传性癌症
  • 伴随诊断
    • 伴随诊断、临床肿瘤学 NGS 市场，2018-2030 年（百万美元）
  • 其他诊断
    • 其他诊断临床肿瘤学 NGS 市场，2018-2030 年（百万美元）

第 7 章临床肿瘤学下一代测序市场分类：最终用途估计和趋势分析

  • 临床肿瘤学 NGS 市场：最终用途变异分析
  • 按最终用途
  • 医院
    • 2018-2030 年医院临床肿瘤 NGS 市场（百万美元）
  • 诊所
    • 临床肿瘤学 NGS 市场，2018-2030 年（百万美元）
  • 实验室
    • 实验室临床肿瘤学 NGS 市场，2018-2030 年（百万美元）

第8章临床肿瘤学下一代测序市场区域业务分析

  • 2022 年和 2030 年临床肿瘤学下一代测序市场份额（按地区）
  • 北美
    • 北美临床肿瘤学下一代测序市场，2018-2030 年（百万美元）
    • 美国
    • 加拿大
  • 欧洲
    • 2018-2030 年欧洲临床肿瘤学下一代测序市场（百万美元）
    • 英国
    • 德国
    • 法国
    • 意大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太临床肿瘤学下一代测序市场（百万美元）
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 泰国
    • 韩国
  • 拉丁美洲
    • 拉丁美洲临床肿瘤学下一代测序市场，2018-2030 年（百万美元）
    • 巴西
    • 墨西哥
    • 阿根廷
  • MEA
    • MEA 临床肿瘤学下一代测序市场，2018-2030 年（百万美元）
    • 南非
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 科威特

第 9 章竞争格局

  • 公司分类
  • 战略规划
  • 公司简介/列表
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • F. Hoffmann-La Roche Ltd
    • Agilent Technologies, Inc.
    • Myriad Genetics, Inc.
    • Beijing Genomics Institute（BGI）
    • QIAGEN
    • Perkin Elmer, Inc.
    • PacBio
    • Partek Incorporated
    • Foundation Medicine Inc.
    • Oxford Nanopore Technologies
    • Paradigm Diagnostics, Inc.
    • Caris Life Sciences
    • Eurofins Scientific
    • PerkinElmer, Inc.
Product Code: GVR-3-68038-791-9

Clinical Oncology Next Generation Sequencing Market Growth & Trends

The global clinical oncology next generation sequencing market size is expected to reach USD 1.16 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 15.7% from 2023 to 2030. The clinical oncology next generation sequencing (NGS) market is in high demand. It is projected to expand at an increasing rate throughout the forecast period owing to the rising healthcare expenditure triggering the development of effective personalized medicine & therapeutic procedures for cancer and increasing adoption of NGS.

The increasing healthcare expenses and the launch of effective cancer treatments are expected to fuel market growth over the forecast period. A study published by the JAMA network in February 2023 estimated that the cost of cancer treatment can reach up to USD 25 trillion globally over the 30 years from 2020-2030. The comparative contribution of treatment expenses to the total economic expense of cancers was found to be more significant in high-income nations than in low-income nations. Moreover, various treatment techniques are being developed and utilized to diagnose and treat cancer. According to the study published by Wiley in January 2023, technological advances that are being used to develop new diagnostic techniques include image reconstruction software, imaging devices, hardware, biomarkers, and artificial intelligence algorithms, thereby delivering a reliable analysis and diagnosis of the tumor.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is propelled by the rise in the adoption of NGS over single gene testing. Many studies demonstrated that NGS is cost-effective and efficient over single gene testing. For instance, a study published by JCO Precision Oncology in March 2023 concluded that the adoption of NGS in Spanish reference centers to diagnose patients with NSCLC could be a cost-effective strategy over single gene testing. In addition, the study given by the National Library of Medicine in January 2023, suggests that the current NGS over sequential single-gene testing can slightly reduce annual costs. However, embracing NSG over SSG testing can decrease the average turnaround time, facilitating quicker identification of genomic alterations and early initiating therapy for small cell lung cancer patients in Japan. These factors are expected to drive the market over the forecast period.

Clinical Oncology Next Generation Sequencing Market Report Highlights

  • In the workflow segment, NGS sequencing dominated the market with a revenue share of 56.0% in 2022, owing to technological advancements and the rising number of cancer sequencing projects
  • By technology, the targeted sequencing and resequencing accounted for the largest revenue share of 72.7% in the clinical oncology NGS market in 2022. This can be attributed to the growing clinical utility of targeted panels and their efficiency in detecting cancer tumors
  • By application, the screening segment held the highest share of 80.1% in 2022. The segment's dominance is due to the increasing prevalence of cancer worldwide
  • By end-use, the laboratories segment accounted for the largest share of 64.1% in the clinical oncology NGS market in 2022. This can be attributed to the rising number of research and development activities
  • North America held the largest market share of 48.68% in 2022. The dominance of the region is due to the presence of prominent international players in the market and rising investments from public and private organizations in life science research & solutions developments in the region

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model
    • 1.4.1. Market Study, By Company Market Share
    • 1.4.2. Regional Analysis

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Decrease in costs for genetic sequencing
      • 3.2.1.2. Advancements in the field of personalized medicine
      • 3.2.1.3. Rise in competition amongst prominent market entities
      • 3.2.1.4. Growing healthcare expenditure triggering development of effective PM diagnostic & therapeutic procedure for cancer
      • 3.2.1.5. Rise in prevalence of cancer
      • 3.2.1.6. Growing adoption of NGS over single gene testing
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Lack of computational efficiency for data management
      • 3.2.2.2. Non-value based NGS reimbursement policy
  • 3.3. Industry Analysis Tools
    • 3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.3.2. Porter's Five Forces Analysis
    • 3.3.3. Penetration and Growth Prospect Mapping, 2022
  • 3.4. COVID-19 Impact Analysis

Chapter 4. Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis

  • 4.1. Clinical Oncology NGS Market: Technology Movement Analysis
  • 4.2. Clinical Oncology NGS Market Estimates & Forecast, By Technology (USD Million)
  • 4.3. Whole Genome Sequencing
    • 4.3.1. Whole Genome Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 4.4. Whole Exome Sequencing
    • 4.4.1. Whole Exome Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted Sequencing & Resequencing
    • 4.5.1. Targeted Sequencing & Resequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)

Chapter 5. Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis

  • 5.1. Clinical Oncology NGS Market: Workflow Movement Analysis
  • 5.2. Clinical Oncology NGS Market Estimates & Forecast, By Workflow (USD Million)
  • 5.3. NGS Pre-Sequencing
    • 5.3.1. NGS Pre-Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 5.4. NGS Sequencing
    • 5.4.1. NGS Sequencing For Clinical Oncology Market, 2018 - 2030 (USD Million)
  • 5.5. NGS Data Analysis
    • 5.5.1. NGS Data Analysis For Clinical Oncology Market, 2018 - 2030 (USD Million)

Chapter 6. Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis

  • 6.1. Clinical Oncology NGS Market: Application Movement Analysis
  • 6.2. Clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 6.3. Screening
    • 6.3.1. Screening Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
    • 6.3.2. Sporadic Cancer
      • 6.3.2.1. Sporadic cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
    • 6.3.3. Inherited cancer
      • 6.3.3.1. Inherited cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 6.4. Companion Diagnostics
    • 6.4.1. Companion diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 6.5. Other Diagnostics
    • 6.5.1. Other diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)

Chapter 7. Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis

  • 7.1. Clinical Oncology NGS Market: End Use Movement Analysis
  • 7.2. Clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
  • 7.3. Hospitals
    • 7.3.1. Hospitals Clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 7.4. Clinics
    • 7.4.1. Clinics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • 7.5. Laboratories
    • 7.5.1. Laboratories clinical oncology NGS market, 2018 - 2030 (USD Million)

Chapter 8. Clinical Oncology Next Generation Sequencing Market Regional Business Analysis

  • 8.1. Clinical Oncology Next Generation Sequencing Market Share By Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North America Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Competitive Scenario
      • 8.2.2.3. Regulatory Framework
      • 8.2.2.4. U.S. Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Competitive Scenario
      • 8.2.3.3. Regulatory Framework
      • 8.2.3.4. Canada Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.3. Europe
    • 8.3.1. Europe Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. Regulatory Framework
      • 8.3.2.4. UK Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Regulatory Framework
      • 8.3.3.4. Germany Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. Regulatory Framework
      • 8.3.4.4. France Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Regulatory Framework
      • 8.3.5.4. Italy Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Regulatory Framework
      • 8.3.6.4. Spain Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.7. Denmark
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Regulatory Framework
      • 8.3.7.4. Denmark Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.8. Sweden
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Regulatory Framework
      • 8.3.8.4. Sweden Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.3.9. Norway
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Regulatory Framework
      • 8.3.9.4. Norway Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Japan Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. China Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. India Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Regulatory Framework
      • 8.4.5.4. Australia Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.6. Thailand
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. Regulatory Framework
      • 8.4.6.4. Thailand Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.4.7. South Korea
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Regulatory Framework
      • 8.4.7.4. South Korea Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.5. Latin America
    • 8.5.1. Latin America Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Brazil Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Mexico Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Argentina Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
  • 8.6. MEA
    • 8.6.1. MEA Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. South Africa Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Saudi Arabia Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. UAE Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Kuwait Clinical Oncology Next Generation Sequencing Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Profiles/Listing
    • 9.3.1. Illumina, Inc.
      • 9.3.1.1. Overview
      • 9.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific Inc.
      • 9.3.2.1. Overview
      • 9.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. F. Hoffmann-La Roche Ltd
      • 9.3.3.1. Overview
      • 9.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Agilent Technologies, Inc.
      • 9.3.4.1. Overview
      • 9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Myriad Genetics, Inc.
      • 9.3.5.1. Overview
      • 9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Beijing Genomics Institute (BGI)
      • 9.3.6.1. Overview
      • 9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. QIAGEN
      • 9.3.7.1. Overview
      • 9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Perkin Elmer, Inc.
      • 9.3.8.1. Overview
      • 9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. PacBio
      • 9.3.9.1. Overview
      • 9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. Partek Incorporated
      • 9.3.10.1. Overview
      • 9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
    • 9.3.11. Foundation Medicine Inc.
      • 9.3.11.1. Overview
      • 9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.11.3. Product Benchmarking
      • 9.3.11.4. Strategic Initiatives
    • 9.3.12. Oxford Nanopore Technologies
      • 9.3.12.1. Overview
      • 9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.12.3. Product Benchmarking
      • 9.3.12.4. Strategic Initiatives
    • 9.3.13. Paradigm Diagnostics, Inc.
      • 9.3.13.1. Overview
      • 9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.13.3. Product Benchmarking
      • 9.3.13.4. Strategic Initiatives
    • 9.3.14. Caris Life Sciences
      • 9.3.14.1. Overview
      • 9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.14.3. Product Benchmarking
      • 9.3.14.4. Strategic Initiatives
    • 9.3.15. Eurofins Scientific
      • 9.3.15.1. Overview
      • 9.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.15.3. Product Benchmarking
      • 9.3.15.4. Strategic Initiatives
    • 9.3.16. PerkinElmer, Inc.
      • 9.3.16.1. Overview
      • 9.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 9.3.16.3. Product Benchmarking
      • 9.3.16.4. Strategic Initiatives

List of Tables

  • Table 1 Cancer Incidence and Mortality, By Region, 2018
  • Table 2 Genes associated with breast and ovarian cancer that can be sequenced by NGS panel
  • Table 3 FDA-Approved NGS Tumor-Profiling Tests for Companion Diagnostics
  • Table 4 Gene-panels used in clinics for Hereditary Breast/Ovarian Cancer (HBOC)
  • Table 5 North America clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 6 North America clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 7 North America clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 8 North America clinical oncology NGS screening market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 9 North America clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 11 U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 12 U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 13 U.S. clinical oncology NGS screening market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 14 U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 15 Canada clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 16 Canada clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 17 Canada clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 18 Canada clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 20 Europe clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 21 Europe clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 24 Germany clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 25 Germany clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 26 Germany clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 27 UK clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 28 UK clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 29 UK clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 30 UK clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 31 France clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 32 France clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 33 France clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 34 France clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 35 Italy clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 36 Italy clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 37 Italy clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 38 Italy clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 39 Spain clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 40 Spain clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 41 Spain clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 42 Spain clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million) 
  • Table 43 Denmark clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 44 Denmark clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 45 Denmark clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 46 Denmark clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million) 
  • Table 47 Sweden clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 48 Sweden clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 49 Sweden clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 50 Sweden clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 51 Norway clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 52 Norway clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 53 Norway clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 54 Norway clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 55 Asia Pacific clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 59 Japan clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 60 Japan clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 61 Japan clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 62 Japan clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 63 China clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 64 China clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 65 China clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 66 China clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 67 India clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 68 India clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 69 India clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 70 India clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 71 South Korea clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 72 South Korea clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 73 South Korea clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 74 South Korea clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 75 Australia clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 76 Australia clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 77 Australia clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 78 Australia clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 79 Thailand clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 80 Thailand clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 81 Thailand clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 82 Thailand clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 83 Latin America clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 84 Latin America clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 85 Latin America clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 86 Latin America clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 87 Brazil clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 88 Brazil clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 89 Brazil clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 90 Brazil clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 91 Mexico clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 92 Mexico clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 93 Mexico clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 94 Mexico clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 95 Argentina clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 96 Argentina clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 97 Argentina clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 98 Argentina clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 99 Middle East & Africa clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 100 Middle East & Africa clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 101 Middle East & Africa clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 102 Middle East & Africa clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 104 South Africa clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 105 South Africa clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 106 South Africa clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 112 UAE clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 113 UAE clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 114 UAE clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait clinical oncology NGS market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
  • Table 116 Kuwait clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
  • Table 117 Kuwait clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • Table 118 Kuwait clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market trends & outlook
  • Fig. 9 Market segmentation & scope
  • Fig. 10 Penetration & growth prospect mapping for application, 2022
  • Fig. 11 Penetration & growth prospect mapping for prominent industry players, 2022
  • Fig. 12 Market driver relevance analysis (Current & future impact)
  • Fig. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
  • Fig. 14 Cost per genome
  • Fig. 15 Expected rise in expenditure for cancer treatment (USD Billion)
  • Fig. 16 Number of new cancer cases in the World, 2022
  • Fig. 17 Market restraint relevance analysis (Current & future impact)
  • Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
  • Fig. 19 Porter's Five Forces Analysis
  • Fig. 20 Strategy framework
  • Fig. 21 Participant categorization
  • Fig. 22 Clinical oncology NGS market: Technology outlook key takeaways
  • Fig. 23 Clinical oncology NGS market: Technology movement analysis
  • Fig. 24 Whole genome sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 25 Whole exome sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 26 Targeted sequencing and resequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 27 Clinical oncology NGS market: Workflow outlook key takeaways
  • Fig. 28 Clinical oncology NGS market: Workflow movement analysis
  • Fig. 29 NGS Pre-sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 30 NGS Sequencing for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 31 NGS Data analysis for clinical oncology market, 2018 - 2030 (USD Million)
  • Fig. 32 Clinical oncology NGS market: Application outlook key takeaways
  • Fig. 33 Clinical oncology NGS market: Application movement analysis
  • Fig. 34 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 35 Sporadic cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 36 Lifetime cancer risks for common cancers
  • Fig. 37 Inherited cancer screening clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 38 Companion diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 39 Other diagnostics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 40 Clinical oncology NGS market: End use outlook key takeaways
  • Fig. 41 Clinical oncology NGS market: End use movement analysis
  • Fig. 42 Hospitals clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 43 Clinics clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 44 Laboratories clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 45 Regional market place: Key takeaway
  • Fig. 46 Clinical oncology NGS market: Regional outlook, 2018 & 2025
  • Fig. 47 North America clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 49 Canada clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 50 Europe clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 51 Germany clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 52 UK clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 53 France clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 54 Italy clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 55 Spain clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 57 Sweden clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 58 Norway clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 59 Asia Pacific clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 60 Japan clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 61 China clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 63 India clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 66 Latin America clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 67 Brazil clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 68 Mexico clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 69 Argentina clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 70 Middle East & Africa clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 72 Saudi Arabia clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 74 Kuwait clinical oncology NGS market, 2018 - 2030 (USD Million)
  • Fig. 75 Key companies profiled